Money and distorted ethical judgments about research: ethical assessment of the TeGenero TGN1412 trial. .Am. J. Bioeth. 7, 76-81.Money and distorted ethical judgments about research: Ethical assessment of the TeGenero TGN1412 Trial - Emanuel, Miller...
TeGenero Mab causes shock side-effects in UK trial.The article reports on the outcome of the phase I clinical trial of TeGenero AG's TGN1412 held in Great Britain which created a controversy after patients suffered serious harmful effects after taking the drug. They revealed that six men ...
Money and distorted ethical judgment about research: ethical assessment of the TeGenero TGN1412 trial. Am J Bioeth 2007;7:76-81.Emanuel EJ, Miller FG. Money and distorted ethical judgments about research: ethical assessment of the TeGenero TGN1412 trial. Am J Bioethics 2007;7:76-81.Emanuel...
The article reports that German biotech firm TeGenero AG has filed for bankruptcy just four months after a catastrophic safety trial with its immunomodulatory drug candidate TGN1412 left six healthy volunteers fighting for their lives. TGN1412 was developed for the treatment of certain autoimmune ...
Using a minimum anticipated biological effect level (MABEL) approach, a much lower dose of TGN1412 would have been used in the first-in-human (FIH) trial. For predicting in vivo effects of a biological, knowledge of the antibody, its target, and the interaction between the two is needed,...
The article reports on the filing of bankruptcy by the TeGenero AG, a German biotech firm, after the safety trial of its TGN1412 drug to six healthy volunteers which left fighting for their lives in London, England. Due to the incidents, the company states that the drug may no longer ...
TeGenero felled by test fiasco.The article reports that TeGenero, the German firm whose monoclonal antibody drug TGN1412 was involved in a disastrous Phase I trial, has filed for bankruptcy.EBSCO_bspChemical & Engineering News
Six men were admitted to intensive care after taking part of the trial. The drug, TGN1412, is a humanized Mab with specificity for the T-lymphocyte surface receptor CD28, a component in the human immune response.EBSCO_bspPharmaWatch: Cancer...